Skip to main navigation
  • Technology
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
    • IR Resources
      • FAQs
      • Email Alerts
      • Contact IR
  • Blog
  • Contact
Nautilus Biotechnology
  • Technology
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financial Information
    • IR Resources
  • Blog
  • Contact

Investor Relations

  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Leadership
    • Board of Directors
    • Committee Composition
  • Financial Information
    • SEC Filings
    • Quarterly and Annual Results
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact IR

Changing the scale of what’s possible…

Nautilus Biotechnology seeks to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. By integrating breakthrough innovations in computer science, engineering, and biochemistry we have designed a large-scale, single molecule proteomic analysis technology capable of delivering extreme sensitivity and scale.

 

By enabling an expansion of both the depth and breadth of proteomic studies, Nautilus’ technology has the potential to revolutionize how biological research is conducted, drugs are identified and developed, and human disease is treated.

Change
Volume
52 Week High
52 Week Low
Dec 5, 2023 11:40 PM EST

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics Award
Society award recognizes Dr. Mallick’s decades of innovative leadership and science advancing the field of computational proteomics SEATTLE, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform
Nov 30, 2023
Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development
Former Quantapore founder and CEO brings 20 years of proteomics and genomics industry experience to company developing a platform for comprehensively quantifying the proteome SEATTLE, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering
Nov 01, 2023
Nautilus Biotechnology Reports Third Quarter 2023 Financial Results
SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2023. “I’m very pleased with the progress Nautilus
Oct 31, 2023

View All

Events
Nautilus Q3 2023 Earnings Conference Call
Oct 31, 2023 at 8:30 AM EDT
Webcast
Gilmartin Group Emerging Growth Company Showcase
Sep 21, 2023 at 10:30 AM EDT
Webcast
Morgan Stanley 21st Annual Global Healthcare Conference
Sep 13, 2023 at 10:50 AM EDT
Webcast

View All

Sign-up for updates

Sign Up

Nautilus Biotechnology

 

 

Corporate Headquarters
2701 Eastlake Avenue East
Seattle, WA 98102

 

 

 

Research Headquarters
835 Industrial Road, Suite 200
San Carlos, CA 94070

Nautilus Biotechnology

 

linkedin      twitter

info@nautilus.bio
+1 (206) 333-2001

© 2023 Nautilus Biotechnology Inc.

Privacy Policy | Terms